[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES8604422A1 - Un procedimiento para obtener una vacuna de coronavirus canino - Google Patents

Un procedimiento para obtener una vacuna de coronavirus canino

Info

Publication number
ES8604422A1
ES8604422A1 ES538588A ES538588A ES8604422A1 ES 8604422 A1 ES8604422 A1 ES 8604422A1 ES 538588 A ES538588 A ES 538588A ES 538588 A ES538588 A ES 538588A ES 8604422 A1 ES8604422 A1 ES 8604422A1
Authority
ES
Spain
Prior art keywords
canine
coronavirus
vaccine
virus
avirulent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES538588A
Other languages
English (en)
Other versions
ES538588A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27054825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8604422(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/504,434 external-priority patent/US4567043A/en
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of ES8604422A1 publication Critical patent/ES8604422A1/es
Publication of ES538588A0 publication Critical patent/ES538588A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/818—Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO DE PRODUCCION DE VACUNAS DE CORONAVIRUS CANINO. COMPRENDE LA INOCULACION DE UNA SUSPENSION DE CULTIVO CELULAR DE TEJIDO DE MAMIFERO CON CORONAVIRUS CANINO; COSECHAR ESTAS CEKULAS DESPUES DE UN TIEMPO DE 24 A 96 HORAS DESDE LA INOCULACION, SEPARANDO LA MONOCAPA DE CELULAS MEDIANTE CONGELACION-DESCONGELACION POR ACCION ENZIMATICA PARA AUMENTAR EL CONTENIDO VIRAL DE LOS FLUIDOS COSECHADOS; RECOGER EL VIRUS PROPAGADO DE LAS CELULAS COSECHADAS; INACTIVAR DICHO VIRUS MEDIANTE AGENTES INACTIVANTES, COMO BETA-PROPIOLACTONA AL 0,01-0,5%, ADICIONADO A FLUIDO DE VIRUS CONTENIDO EN LOS RECIPIENTES DE PROPAGACION, Y CONTROL DEL PH MEDIANTE HIDROXIDO SODICO O BICARBONATO SODICO; Y ADICIONAR UN COADYUVANTE O MEZCLAS DE ESTOS A LA COMPOSICION INACTIVADA. ESTAS VACUNAS TIENEN APLICACIONES PARA EL TRATAMIENTO DE INFECCIONES EN PERROS.
ES538588A 1983-06-15 1984-12-14 Un procedimiento para obtener una vacuna de coronavirus canino Expired ES8604422A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/504,434 US4567043A (en) 1983-06-15 1983-06-15 Canine corona virus vaccine
US06/618,638 US4567042A (en) 1983-06-15 1984-06-07 Inactivated canine coronavirus vaccine
EP84902632A EP0145783B2 (en) 1983-06-15 1984-06-14 Canine coronavirus vaccine

Publications (2)

Publication Number Publication Date
ES8604422A1 true ES8604422A1 (es) 1986-02-01
ES538588A0 ES538588A0 (es) 1986-02-01

Family

ID=27054825

Family Applications (1)

Application Number Title Priority Date Filing Date
ES538588A Expired ES8604422A1 (es) 1983-06-15 1984-12-14 Un procedimiento para obtener una vacuna de coronavirus canino

Country Status (7)

Country Link
US (1) US4567042A (es)
EP (4) EP0345911B1 (es)
AT (4) ATE280217T1 (es)
DE (4) DE3486293T3 (es)
ES (1) ES8604422A1 (es)
NL (1) NL940017I2 (es)
WO (1) WO1985000014A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990367A (en) * 1987-03-09 1991-02-05 Diamond Scientific Company Canine distemper virus vaccine
ES2052685T3 (es) * 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5565209A (en) * 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine
US5911999A (en) * 1987-09-28 1999-06-15 Pfizer, Inc. Vaccine based on TGEV for protection of dogs against canine coronavirus
US5232694A (en) * 1989-05-03 1993-08-03 Akzo N.V. Canine corona virus vaccine
US5672350A (en) * 1989-08-22 1997-09-30 Veterinary Infectious Disease Organization Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US6372224B1 (en) 1990-11-14 2002-04-16 Pfizer Inc. Canine coronavirus S gene and uses therefor
US6057436A (en) * 1990-11-14 2000-05-02 Pfizer Inc. Canine coronavirus S gene and uses therefor
DE69233270T2 (de) * 1991-04-25 2004-09-30 Akzo Nobel N.V. Subeinheits-Impfstoff gegen Hundecoronavirus
US5750112A (en) * 1993-02-26 1998-05-12 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US7790178B2 (en) 2002-12-19 2010-09-07 Intervet International B.V. Trivalent vaccine with maternal anitbody transfer via the milk
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
CN1835767A (zh) * 2003-01-29 2006-09-20 辉瑞产品公司 对抗支气管败血性博德特氏杆菌的犬疫苗
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
JP2007508837A (ja) * 2003-10-23 2007-04-12 ファイザー・プロダクツ・インク 歯周疾患のためのワクチン
EP1871410A2 (en) * 2005-04-07 2008-01-02 Pharmacia & Upjohn Company LLC Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
PT1780216E (pt) * 2005-10-26 2011-02-03 Canio Buonavoglia Coronavírus canino pantrópico
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
KR101013226B1 (ko) * 2008-05-14 2011-02-10 녹십자수의약품(주) 개 바이러스성 설사병 예방용 백신
US20110110980A1 (en) * 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
UY34745A (es) 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
WO2020142778A1 (en) 2019-01-04 2020-07-09 Boehringer Ingelheim Animal Health USA Inc. Attenuated bordetella bronchiseptica strains, oral vaccines containing the attenuated strains, and methods of making & use thereof
CN109765384B (zh) * 2019-01-29 2022-11-18 北京勤邦生物技术有限公司 一种犬冠状病毒抗体荧光检测试纸条及其制备方法和应用
CN112402599B (zh) * 2019-08-23 2023-06-27 中国农业科学院特产研究所 一种犬用犬瘟热、细小病毒病二联灭活疫苗及其制备方法
JPWO2022149342A1 (es) * 2021-01-06 2022-07-14

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3143474A (en) * 1962-07-30 1964-08-04 Sterling Drug Inc Preparation of duck-embryo modified infectious canine hepatitis virus vaccine
US3704203A (en) † 1967-08-24 1972-11-28 Diamond Lab Inc Transmissible gastroenteritis vaccines and methods of producing the same
US3652761A (en) * 1969-09-04 1972-03-28 Corning Glass Works Immunochemical composites and antigen or antibody purification therewith
US3959251A (en) * 1970-06-25 1976-05-25 Exploaterings Aktiebolaget T.B.F. Stabilized agar product and method for its stabilization

Also Published As

Publication number Publication date
EP0145783A1 (en) 1985-06-26
DE3481582D1 (de) 1990-04-19
EP0329264B1 (en) 1994-03-23
EP0145783B1 (en) 1990-03-14
ATE103180T1 (de) 1994-04-15
EP0345911B1 (en) 2004-10-20
NL940017I2 (nl) 2001-02-01
DE3486293T2 (de) 1994-06-30
NL940017I1 (nl) 1994-10-17
DE3486292T2 (de) 1994-06-30
ATE103181T1 (de) 1994-04-15
DE3486293T3 (de) 2002-11-21
EP0344872B1 (en) 1994-03-23
WO1985000014A1 (en) 1985-01-03
ATE50913T1 (de) 1990-03-15
DE3486293D1 (de) 1994-04-28
EP0329264A2 (en) 1989-08-23
EP0145783A4 (en) 1985-10-14
EP0329264A3 (en) 1989-12-13
EP0345911A1 (en) 1989-12-13
US4567042A (en) 1986-01-28
ATE280217T1 (de) 2004-11-15
EP0145783B2 (en) 2004-01-02
DE3486293T4 (de) 1995-06-14
DE3486292D1 (de) 1994-04-28
ES538588A0 (es) 1986-02-01
EP0344872A1 (en) 1989-12-06
DE3486495D1 (de) 2004-11-25
EP0344872B2 (en) 2002-04-24

Similar Documents

Publication Publication Date Title
ES8604422A1 (es) Un procedimiento para obtener una vacuna de coronavirus canino
JP3993230B2 (ja) 改良された修飾ｂｒｓｖ生ワクチン
Holder et al. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies
McVicar et al. Growth of foot-and-mouth disease virus in the upper respiratory tract of non-immunized, vaccinated, and recovered cattle after intranasal inoculation
Sharma Embryo vaccination with infectious bursal disease virus alone or in combination with Marek's disease vaccine
AU7589587A (en) Low dosage of interferon to enhance vaccine efficiency
Buonavoglia et al. Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine
ES8201020A1 (es) Un procedimiento para preparar una vacuna de virus vivos de la peritonitis infecciosa de los felinos
US5928649A (en) Method of reversing immunosuppression in vaccines
Nakao et al. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein
EP0894500B1 (en) Streptococcus equi vaccine
Lopez et al. Immune response to foot-and-mouth disease virus in an experimental murine model II. Basis of persistent antibody reaction
US4049794A (en) Treatment of infections in animals
Merza et al. ISCOM of BHV‐1 Envelope Glycoproteins Protected Calves Against Both Disease and Infection
US4039656A (en) Production of attenuated viruses
Visser Vaccination strategies for improving the efficacy of programs to eradicate Aujeszky's disease virus
Kimman Comparative efficacy of three doses of the genetically engineered Aujeszky's disease virus vaccine strain 783 in pigs with maternal antibodies
Morein et al. Vaccination against herpesvirus, fiction or reality
林俊春 et al. Role of thymus-dependent lymphocytes and antibodies in feline infectious peritonitis after oral infection.
Gough et al. Lactogenic immunity to transmissible gastroenteritis virus induced by a subunit immunogen
Ashe et al. Inapparent herpes simplex virus infection in inoculated rabbits
US4017359A (en) Production of non-antigenic attenuated viruses
NZ192271A (en) Inactivated feline infectious peritonitis (fip) vaccine
Olsen et al. Experimental Oncornavirus Vaccines in the Cat 1
Gough et al. A viral subunit immunogen for porcine transmissible gastroenteritis

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20051119